Search Results - "AL, Maiwenn J"

Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy by Kiel, Menno A., MD, MSc, Röder, Esther, MD, PhD, Gerth van Wijk, Roy, MD, PhD, Al, Maiwenn J., PhD, Hop, Wim C.J., PhD, Rutten-van Mölken, Maureen P.M.H., PhD

“…Background Subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) are safe and effective treatments of allergic rhinitis, but…”
Get full text

Impact of hospitalisation on health-related quality of life in patients with chronic heart failure by Albuquerque de Almeida, Fernando, Al, Maiwenn J, Koymans, Ron, Riistama, Jarno, Pauws, Steffen, Severens, Johan L

“…Empirical identification of the direct impact of hospitalisation in the change in utility could provide an interpretation for some of the unexplained variance…”
Get full text

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations by Holleman, Marscha S., Al, Maiwenn J., Zaim, Remziye, Groen, Harry J. M., Uyl-de Groot, Cari A.

“…Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC)…”
Get full text

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis by Alemao, Evo, Al, Maiwenn J, Boonen, Annelies A, Stevenson, Matthew D, Verstappen, Suzanne M M, Michaud, Kaleb, Weinblatt, Michael E, Rutten-van Mölken, Maureen P M H

“…The objective of this study was to evaluate current approaches to economic modeling in rheumatoid arthritis (RA) and propose a new conceptual model for…”
Get full text

A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data by Corro Ramos, Isaac, PhD, van Voorn, George A.K., PhD, Vemer, Pepijn, PhD, Feenstra, Talitha L., PhD, Al, Maiwenn J., PhD

“…Abstract Background The validation of health economic (HE) model outcomes against empirical data is of key importance. Although statistical testing seems…”
Get full text

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes by Vemer, Pepijn, Al, Maiwenn J, Oppe, Mark, Rutten-van Mölken, Maureen P M H

“…Decision-analytic cost-effectiveness (CE) models combine many parameters, often obtained after meta-analysis. We compared different methods of mixed-treatment…”
Get full text

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients by van de Laar, Celine Johanna, Janssen, Carly A, Janssen, Matthijs, Oude Voshaar, Martijn A H, Al, Maiwenn J, van de Laar, Mart A F J

“…To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed…”
Get full text

Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis by Ramos, Isaac Corro, PhD, P.M.H., Maureen, PhD, Mölken, Rutten-van, Al, Maiwenn J., PhD

“…Abstract Background The conditional reimbursement policy for expensive medicines in The Netherlands requires data collection on actual use and…”
Get full text

Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease by Hoogendoorn, Martine, MSc, Rutten-van Mölken, Maureen P.M.H., PhD, Hoogenveen, Rudolf T., MSc, Al, Maiwenn J., PhD, Feenstra, Talitha L., PhD

“…Abstract Objectives To develop a stochastic population model of disease progression in chronic obstructive pulmonary disease (COPD) that includes the effects…”
Get full text

Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research by Oostenbrink, Jan B., PhD, Al, Maiwenn J., PhD, Oppe, Mark, MSc, Rutten-van Mölken, Maureen P.M.H., PhD

“…Abstract Objective Value of information (VOI) analysis informs decision-makers about the expected value of conducting more research to support a decision. This…”
Get full text

Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis by Alemao, Evo, Johal, Sukhvinder, Al, Maiwenn J., Rutten-van Mölken, Maureen

“…To assess cost effectiveness of abatacept versus adalimumab, each administered with methotrexate, in treating patients with rheumatoid arthritis (RA)…”
Get full text

Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands by Al, Maiwenn J., PhD, Maniadakis, Nikos, PhD, Grijseels, Els W.M., PhD, MD, Janssen, Matthijs, PhD, MD

“…Abstract Objective To assess the balance between costs and upper gastrointestinal (GI) side effects of treatment with celecoxib, nonsteroidal antiinflammatory…”
Get full text

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis by Holleman, Marscha S, van Tinteren, Harm, Groen, Harry Jm, Al, Maiwenn J, Uyl-de Groot, Carin A

“…EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of…”
Get full text

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Büyükkaramikli, Nasuh C., de Groot, Saskia, Riemsma, Rob, Fayter, Debra, Armstrong, Nigel, Portegijs, Piet, Duffy, Steven, Kleijnen, Jos, Al, Maiwenn J.

“…The National Institute for Health and Care Excellence, as part of the institute’s single technology appraisal process, invited the manufacturer of ribociclib…”
Get full text

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.

“…The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza ® , Eli Lilly and Company) to submit…”
Get full text

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data by Alemao, Evo, Joo, Seongjung, Kawabata, Hugh, Al, Maiwenn J., Allison, Paul D., Rutten‐van Mölken, Maureen P. M. H., Frits, Michelle L., Iannaccone, Christine K., Shadick, Nancy A., Weinblatt, Michael E.

“…Objective To evaluate associations between achieving guideline‐recommended targets of disease activity, defined by the Disease Activity Score in 28 joints…”
Get full text

The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios by Franken, Margreet G, Corro Ramos, Isaac, Los, Jeanine, Al, Maiwenn J

“…In an ageing population, it is inevitable to improve the management of care for community-dwelling elderly with incontinence. A previous study showed that…”
Get full text

Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework by Corro Ramos, Isaac, Lhachimi, Stefan K., Gerber-Grote, Andreas, Al, Maiwenn J.

“…Background. The National Institute for Quality and Efficiency in Health Care (IQWiG) employs an efficiency frontier (EF) framework to facilitate setting…”
Get full text

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal by Büyükkaramikli, Nasuh C., de Groot, Saskia, Fayter, Debra, Wolff, Robert, Armstrong, Nigel, Stirk, Lisa, Worthy, Gill, Albuquerque de Almeida, Fernando, Kleijnen, Jos, Al, Maiwenn J.

“…The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of…”
Get full text

The analysis of incomplete cost data due to dropout by Oostenbrink, Jan B., Al, Maiwenn J.

“…Incomplete data due to premature withdrawal (dropout) constitute a serious problem in prospective economic evaluations that has received only little attention…”
Get full text